BRPI0509298A - composto, composição farmacêutica, métodos de inibir receptor h3 de histamina em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, obesidade, e um distúrbio ou doença, e, uso de um composto - Google Patents
composto, composição farmacêutica, métodos de inibir receptor h3 de histamina em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, obesidade, e um distúrbio ou doença, e, uso de um compostoInfo
- Publication number
- BRPI0509298A BRPI0509298A BRPI0509298-1A BRPI0509298A BRPI0509298A BR PI0509298 A BRPI0509298 A BR PI0509298A BR PI0509298 A BRPI0509298 A BR PI0509298A BR PI0509298 A BRPI0509298 A BR PI0509298A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- disorder
- methods
- receptor
- obesity
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 102000004384 Histamine H3 receptors Human genes 0.000 title abstract 3
- 108090000981 Histamine H3 receptors Proteins 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 208000035475 disorder Diseases 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 229940115480 Histamine H3 receptor antagonist Drugs 0.000 abstract 1
- 229940122931 Histamine H3 receptor inverse agonist Drugs 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 abstract 1
- 201000003631 narcolepsy Diseases 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55854204P | 2004-04-01 | 2004-04-01 | |
| US61710104P | 2004-10-08 | 2004-10-08 | |
| PCT/US2005/010240 WO2005097740A1 (en) | 2004-04-01 | 2005-03-25 | Histamine h3 receptor agents, preparation and therapeutic uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0509298A true BRPI0509298A (pt) | 2007-09-18 |
Family
ID=34964070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0509298-1A BRPI0509298A (pt) | 2004-04-01 | 2005-03-25 | composto, composição farmacêutica, métodos de inibir receptor h3 de histamina em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, obesidade, e um distúrbio ou doença, e, uso de um composto |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7632857B2 (enExample) |
| EP (1) | EP1735278B1 (enExample) |
| JP (1) | JP4777974B2 (enExample) |
| CN (1) | CN1960969B (enExample) |
| AT (1) | ATE454372T1 (enExample) |
| AU (1) | AU2005230881B9 (enExample) |
| BR (1) | BRPI0509298A (enExample) |
| CA (1) | CA2561628C (enExample) |
| CY (1) | CY1109860T1 (enExample) |
| DE (1) | DE602005018758D1 (enExample) |
| DK (1) | DK1735278T3 (enExample) |
| ES (1) | ES2337376T3 (enExample) |
| MX (1) | MXPA06011167A (enExample) |
| PL (1) | PL1735278T3 (enExample) |
| PT (1) | PT1735278E (enExample) |
| SI (1) | SI1735278T1 (enExample) |
| WO (1) | WO2005097740A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8008301B2 (en) * | 2004-04-01 | 2011-08-30 | Eli Lilly And Company | Histamine H3 receptor agents, preparation and therapeutic uses |
| EP1784400B1 (en) * | 2004-08-23 | 2015-01-14 | Eli Lilly And Company | Histamine h3 receptor agents, preparation and therapeutic uses |
| GT200600042A (es) * | 2005-02-10 | 2006-09-27 | Aventis Pharma Inc | Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a |
| CN101151244B (zh) * | 2005-04-01 | 2014-09-03 | 伊莱利利公司 | 组胺h3受体活性剂、制备和治疗用途 |
| JP5193033B2 (ja) * | 2005-07-01 | 2013-05-08 | イーライ リリー アンド カンパニー | ヒスタミンｈ３受容体薬剤、製剤及び治療的使用 |
| US8158673B2 (en) * | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| WO2007055418A1 (ja) * | 2005-11-10 | 2007-05-18 | Banyu Pharmaceutical Co., Ltd. | アザ置換スピロ誘導体 |
| ATE485294T1 (de) | 2005-11-18 | 2010-11-15 | Hoffmann La Roche | Azaindol-2-carboxamid-derivate |
| US7351708B2 (en) | 2005-12-16 | 2008-04-01 | Hoffmann-La Roche Inc. | Pyrrolo [2,3-b] pyridine derivatives |
| AU2007227681A1 (en) * | 2006-03-15 | 2007-09-27 | Wyeth | N-substituted-azacyclylamines as histamine-3 antagonists |
| WO2008005338A1 (en) * | 2006-06-29 | 2008-01-10 | Arena Pharmaceuticals, Inc. | Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto |
| TW200823204A (en) * | 2006-10-17 | 2008-06-01 | Arena Pharm Inc | Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto |
| JP2010529130A (ja) * | 2007-06-08 | 2010-08-26 | アリーナ ファーマシューティカルズ， インコーポレイテッド | （ｒ）−１−｛２−［４’−（３−メトキシ−プロパン−１−スルホニル）−ビフェニル−４−イル］−エチル｝−２−メチル−ピロリジンの結晶形、およびその組成物ならびにそれに関連する方法 |
| CA2700691A1 (en) * | 2007-10-01 | 2009-04-09 | F. Hoffmann-La Roche Ag | New biaryl derivatives |
| ES2479440T3 (es) * | 2008-01-30 | 2014-07-24 | Cephalon, Inc. | Derivados de piridazina sustituidos que tienen actividad antagonista de histamina H3 |
| JP5805792B2 (ja) * | 2011-02-23 | 2015-11-10 | スヴェン・ライフ・サイエンシズ・リミテッド | ヒスタミンｈ３レセプターリガンドとしての新規な化合物 |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| MD20140130A2 (ro) | 2012-06-29 | 2015-04-30 | Pfizer Inc. | 4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2 |
| CN112521369A (zh) | 2013-03-13 | 2021-03-19 | 福马治疗股份有限公司 | 用于抑制fasn的化合物及组合物 |
| WO2015092592A1 (en) | 2013-12-17 | 2015-06-25 | Pfizer Inc. | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| JP6633618B2 (ja) * | 2014-08-21 | 2020-01-22 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 強力なｒｏｃｋ阻害剤としてのタイドバックのベンズアミド誘導体 |
| MY189453A (en) | 2015-06-03 | 2022-02-14 | Bristol Myers Squibb Co | 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders |
| RS62639B1 (sr) | 2015-07-06 | 2021-12-31 | Alkermes Inc | Hetero-halo inhibitori histonskih deacetilaza |
| EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| RU2722149C1 (ru) | 2015-09-14 | 2020-05-27 | Пфайзер Инк. | Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2 |
| JP6756925B2 (ja) | 2017-01-11 | 2020-09-16 | ロダン・セラピューティクス，インコーポレーテッド | ヒストンデアセチラーゼの二環式阻害剤 |
| ES2914355T3 (es) | 2017-08-07 | 2022-06-09 | Alkermes Inc | Inhibidores bicíclicos de la histona desacetilasa |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| WO2020092395A1 (en) | 2018-10-29 | 2020-05-07 | Forma Therapeutics, Inc. | SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE |
| US20230257357A1 (en) * | 2020-06-29 | 2023-08-17 | Bacainn Biotherapeutics, Ltd. | Probenecid compounds for the treatment of inflammasome-mediated lung disease |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2579596B1 (fr) | 1985-03-26 | 1987-11-20 | Inst Nat Sante Rech Med | (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique |
| FR2671083B1 (fr) | 1990-12-31 | 1994-12-23 | Inst Nat Sante Rech Med | Nouvelles 4-(4-imidazolyl) piperidines substituees en 1, leur preparation ainsi que leurs applications therapeutiques. |
| US5652258A (en) | 1995-05-30 | 1997-07-29 | Gliatech, Inc. | 2-(4-imidazoyl) cyclopropyl derivatives |
| CA2222099A1 (en) | 1995-05-30 | 1996-12-05 | Gliatech, Inc. | 1h-4(5)-substituted imidazole derivatives |
| PL328369A1 (en) | 1996-02-09 | 1999-01-18 | Black James Foundation | Ligands of histamin h receptor |
| US6620839B2 (en) * | 2000-07-13 | 2003-09-16 | Abbott Laboratories | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
| AU2002254114A1 (en) | 2001-03-23 | 2002-10-08 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
| PL371435A1 (en) * | 2002-02-01 | 2005-06-13 | Novo Nordisk A/S | Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes |
| AU2004215428B2 (en) * | 2003-02-26 | 2009-08-27 | Sugen LLC | Aminoheteroaryl compounds as protein kinase inhibitors |
| EP1720861A2 (en) | 2004-02-25 | 2006-11-15 | Eli Lilly And Company | Histamine h3 receptor antagonists, preparation and therapeutic uses |
-
2005
- 2005-03-25 CA CA2561628A patent/CA2561628C/en not_active Expired - Fee Related
- 2005-03-25 SI SI200530961T patent/SI1735278T1/sl unknown
- 2005-03-25 DE DE602005018758T patent/DE602005018758D1/de not_active Expired - Lifetime
- 2005-03-25 PT PT05730691T patent/PT1735278E/pt unknown
- 2005-03-25 US US10/599,488 patent/US7632857B2/en not_active Expired - Fee Related
- 2005-03-25 MX MXPA06011167A patent/MXPA06011167A/es active IP Right Grant
- 2005-03-25 AU AU2005230881A patent/AU2005230881B9/en not_active Ceased
- 2005-03-25 CN CN2005800171466A patent/CN1960969B/zh not_active Expired - Lifetime
- 2005-03-25 PL PL05730691T patent/PL1735278T3/pl unknown
- 2005-03-25 BR BRPI0509298-1A patent/BRPI0509298A/pt not_active IP Right Cessation
- 2005-03-25 ES ES05730691T patent/ES2337376T3/es not_active Expired - Lifetime
- 2005-03-25 WO PCT/US2005/010240 patent/WO2005097740A1/en not_active Ceased
- 2005-03-25 JP JP2007506412A patent/JP4777974B2/ja not_active Expired - Fee Related
- 2005-03-25 EP EP05730691A patent/EP1735278B1/en not_active Expired - Lifetime
- 2005-03-25 DK DK05730691.2T patent/DK1735278T3/da active
- 2005-03-25 AT AT05730691T patent/ATE454372T1/de active
-
2010
- 2010-02-25 CY CY20101100183T patent/CY1109860T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1735278A1 (en) | 2006-12-27 |
| MXPA06011167A (es) | 2007-01-25 |
| JP2007530698A (ja) | 2007-11-01 |
| US7632857B2 (en) | 2009-12-15 |
| PL1735278T3 (pl) | 2010-06-30 |
| AU2005230881B2 (en) | 2011-03-31 |
| JP4777974B2 (ja) | 2011-09-21 |
| ES2337376T3 (es) | 2010-04-23 |
| DE602005018758D1 (de) | 2010-02-25 |
| US20070208024A1 (en) | 2007-09-06 |
| EP1735278B1 (en) | 2010-01-06 |
| CN1960969B (zh) | 2012-03-28 |
| CN1960969A (zh) | 2007-05-09 |
| SI1735278T1 (sl) | 2010-05-31 |
| DK1735278T3 (da) | 2010-04-12 |
| AU2005230881A1 (en) | 2005-10-20 |
| WO2005097740A1 (en) | 2005-10-20 |
| CA2561628A1 (en) | 2005-10-20 |
| ATE454372T1 (de) | 2010-01-15 |
| AU2005230881B9 (en) | 2011-08-25 |
| CY1109860T1 (el) | 2014-09-10 |
| CA2561628C (en) | 2012-05-08 |
| PT1735278E (pt) | 2010-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0509298A (pt) | composto, composição farmacêutica, métodos de inibir receptor h3 de histamina em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, obesidade, e um distúrbio ou doença, e, uso de um composto | |
| BRPI0514553A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor de histamina h3 em um mamìfero, para o tratamento de um distúrbio do sistema nervoso, para o tratamento de obesidade e para o tratamento de um distúrbio ou doença, e, uso de um composto ou um sal do mesmo | |
| BR122019017036B8 (pt) | compostos de arilamidas substituídas por tetrazol, usos dos referidos compostos e composição farmacêutica | |
| BRPI0508461A (pt) | diaminopirimidinas como antagonistas de p2x3 e p2x2/3 | |
| IL184932A0 (en) | Glucagon receptor antagonists, preperation and therapeutic uses | |
| BRPI0507497A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, e, métodos para prevenir e/ou tratar distúrbios mediados por receptor de mglur5 e para inibir a ativação de receptores de mglur5 | |
| BRPI0821266B8 (pt) | Derivados de arilamida triazol-substituída e seu uso e composição farmacêutica | |
| CY1109787T1 (el) | Ανταγωνιστες υποδοχεα γλυκογονου, παρασκευη και θεραπευτικες χρησεις | |
| BRPI0519124A2 (pt) | composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço | |
| BR112022024875A2 (pt) | Antagonista de receptor crf1 para o tratamento de hiperplasia adrenal congênita | |
| BRPI0407097A (pt) | Antagonista do casr | |
| BR0309486A (pt) | Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas | |
| BRPI0413693A (pt) | composição farmacêutica para a prevenção e tratamento da viciação em um mamìfero | |
| DK1957484T3 (da) | Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser | |
| BRPI0811478A8 (pt) | compostos de morphinan | |
| ATE473961T1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| BRPI0511642A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor h3 da histamina em um mamìfero, para tratamento ou prevenção de um distúrbio do sistema nervoso ou outro distúrbio associado com o receptor h3 da histamina, para tratamento ou prevenção da obesidade, para tratamento ou prevenção de um distúrbio ou doença, e, uso de um composto ou um sal do mesmo | |
| ATE450503T1 (de) | Pyrrolidinderivate als histamin-h3- rezeptorantagonisten | |
| ATE523488T1 (de) | Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung | |
| SI1805169T1 (sl) | Inhibitorji histamin h3 receptorja, njihova priprava in terapevtske uporabe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |